Nikhil I. Khushalani, MD | Authors


Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma

July 08, 2019

Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.